Recovery Act Limited Competition: Research to Address the Heterogeneity in Autism Spectrum Disorders (R21)

archived

Purpose. This NIH Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, solicits applications for the following topic areas relevant to research on the heterogeneity of Autism Spectrum Disorders (ASD): Measurement development, Biomarkers/biological signatures, Immune and central nervous systems interactions, Genetics/genomics, Environmental Risk Factors, Model development, Treatment and intervention, and Services research. This FOA provides support for the R21 grant mechanism which supports initial technical development and proof-of-principle and research in exploratory or preliminary phases. The R21 mechanism is intended to encourage new exploratory and developmental research projects where preliminary data are not required. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental Research Grant (R21) award mechanism and runs essentially in parallel with: 1) an FOA of identical scientific scope, RFA-MH-09-173, that solicits applications under the NIH Clinical Exploratory/Developmental Grant (R34/Collaborative R34) award mechanism, and would be used for early phases of treatment development, and 2) RFA-MH-09-170 and RFA-MH-09-171 that solicit applications under the NIH Research Project Grant Program (R01) and the Collaborative (R01) which would be used for larger scale studies for which preliminary data exists. Funds Available and Anticipated Number of Awards. The NIH intends to commit approximately $57,000,000 to fund between 40-50 grants in response to this FOA and the companion announcements, pending the number and quality of applications and availability of funds.

High